Prana Biotechnology Limited (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

PRAN 1.01 -0.01 (-0.98%)
price chart
Sadif downgrades Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) to Above Average
Sadif is not impressed with the situation of Prana Biotechnology Limited (ADR) (NASDAQ:PRAN). As such, the firm has moved to downgrading its ratings on the stock to Above Average from Good.
Abnormal Volume Spikes: United Online (NASDAQ:UNTD), Prana Biotechnology ...
Prana Biotechnology Limited (ADR)(NASDAQ:PRAN) last session's volume of 896,711shares was higher than its average volume of 138,882shares.
Prana Biotechnology Stock Surges On Approval
Prana Biotechnology Limited (ADR) (PRAN) is up over 30% during trading today on the back of orphan drug designation for its drug PBT2.
Related articles »  
Sadif Downgrades Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) As Atlantic ...
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has been downgraded to Above Average from Good at Sadif. The analysts have noted some weaknesses in the company and believe that its future could be more challenging than the present.
Down 70%: Is Prana Biotechnology Ltd. a Buy?
The biggest loser today in the biotech space was Prana Biotechnology (NASDAQ:PRAN), down a massive 70% because its candidate Alzheimer's drug PBT2 failed its phase 2 trial.
Why Prana Biotech's & Momenta Pharma's Stock Prices Fell Yesterday  Bidness Etc
Prana Biotech Plunges 76%; Drug Fails in Alzheimer Study  Bloomberg
Related articles »  
Prana Biotechnology Limited (ADR) (PRAN) news: Prana Biotechnology - A Gamble ...
One company in particular, Prana Biotechnology (NASDAQ:PRAN), is well-positioned to address this market with their lead drug, and in a realistic but optimistic scenario, the share price could ducuple (increase by 10 times) by the end of the month.
Prana Biotechnology Limited (ADR) (PRAN) news: Prana: Right Drug, Wrong Dose
Prana Biotechnology Limited (NASDAQ:PRAN) is expected to release the results from its Phase 2b IMAGINE trial of PBT2 for the treatment of Alzheimer's disease within the coming month.
Why Prana Biotechnology Limited and Medbox Inc. Lost Big Today
Prana Biotechnology Limited (NASDAQ:PRAN) and Medbox Inc. (NASDAQOTH:MDBX) were the big losers in the health-care space today, and in this segment from Wednesday's Market Checkup, Motley Fool health-care analyst David Williamson looks at ...
Related articles »  
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN): The Research Programs Will Go On
Boston, MA, 04/09/2014 (usastockreport) - Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) announces issue of ordinary shares to carry out its business proceeds.
Related articles »  
Ask a Fool: What's Your Foolish Take on Prana Biotechnology?
Any successful treatment to emerge for either of these indications would be a blockbuster, but real success has been extremely limited here, as these disorders are proving extremely difficult to crack. David cites an article from Summer Street today ...
Related articles »